drugset / Trial / NCT02285244

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

NCT02285244

Phase 2 Withdrawn James Blachly Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well sotrastaurin acetate works in treating patients with chronic lymphocytic leukemia, small lymphocytic leukemia, prolymphocytic leukemia, or Richter's transformation that has returned or that does not respond to treatment. Sotrastaurin acetate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2015-03-12
Primary completion
2015-03-12
Completion
2015-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject sotrastaurin Small molecule Oral